Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review

Kam Hon Yoon, Kam Hon Yoon

Abstract

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease with involvement of both B cells and cytotoxic T lymphocytes and several cytokines aberrations. Standard therapy for SLE has its limitations. Tacrolimus, a novel calcineurin inhibitor with potent immunosuppressive effects, has been shown in the recent years to be effective in SLE therapy. This paper serves to collate the experimental and clinical data on the efficacy of tacrolimus in the treatment of SLE and lupus nephritis. Tacrolimus as a key component of multitarget therapy in SLE is also discussed. The immunocytokine modulatory effects of tacrolimus are also reviewed with reference to SLE. It can be concluded that tacrolimus has an established role in the management of SLE.

References

    1. Lau CS. Who’s afraid of the big bad wolf? Fifth Tay Chong Hai lecture of the national arthritis foundation of Singapore. APLAR Journal of Rheumatology. 2004;7(1):83–89.
    1. De Albuquerque DA, Ebling FM, Lienesch DW, Singh RR, Hahn BH. Analyses of serum levels of type 1, type 2 and type 3 cytokines reveal multiple abnormalities in lupus-prone (NZB × NZW) F1 mice. APLAR Journal of Rheumatology. 2004;7(1):3–10.
    1. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2000;18(5):565–570.
    1. Takabayashi K, Koike T, Kurasawa K, et al. Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. Clinical Immunology and Immunopathology. 1989;51(1):110–117.
    1. Entani C, Izumino Y, Iida H, et al. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron. 1993;64(3):471–475.
    1. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus: a report of three cases. Annals of the Rheumatic Diseases. 1997;56(11):690–692.
    1. Walker SL, Kirby B, Chalmers RJG. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. British Journal of Dermatology. 2002;147(2):405–406.
    1. Kanekura T, Yoshii N, Terasaki K, Miyoshi H, Kanzaki T. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. British Journal of Dermatology. 2003;148(2):353–356.
    1. Madan V, August PJ, Chalmers RJ. Efficacy of topical tacolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clinical and Experimental Dermatology. 2010;35(1):27–30.
    1. Yoshie K, Nahoko T, Kaichi K, et al. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. Modern Rheumatology. 2009;19(6):329–333.
    1. Yoon KH. Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases. APLAR Journal of Rheumatology. 2004;7(1):44–48.
    1. Suzanne CL, Yukiko K, Kenneth L, et al. Treatment of pediatric patients with severe systemic lupus erythematosus with tacrolimus. Annals of Rheumatic Diseases. 2003;(supplement):48–49.
    1. Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney International. 2005;68(2):813–817.
    1. Zhang HT, Hu WX, Xie HL, et al. Tacrolimus versus intravenous cyclophosphamide in the induction therapy of diffuse proliferative lupus nephritis. Nephrology Dialysis Transplantation. 2006;15:501–507.
    1. Maruyama M, Yamasaki Y, Sada K, et al. Good response of membranous lupus nephritis to tacrolimus. Clinical Nephrology. 2006;65(4):276–279.
    1. Szeto C-C, Kwan BC-H, Lai FM-M, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology. 2008;47(11):1678–1681.
    1. Tse KC, Lam MF, Tang SCW, Tang CSO, Chan TM. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus. 2007;16(1):46–51.
    1. Yukari A, Keiko U, Shigeru O, et al. Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center. Nephron Clinical Practice. 2009;113:330–336.
    1. Nobuyuki M, Shinichi K, Hiroshi H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Modern Rheumatology. 2009;19(6):606–615.
    1. Bao H, Liu ZH, Xie H-L, Hu W-X, Zhang H-T, Li L-S. Successful treatment of class V+IV lupus nephritis with multitarget therapy. Journal of the American Society of Nephrology. 2008;19(10):2001–2010.
    1. Zhang HT, Hu WX, Xie HL, et al. Randomized controlled trial of tacrolimus versus intravenous cyclophosphamide in the induction therapy of class V plus IV lupus nephritis. Nephrology Dialysis Transplantation. 2006;15:508–514.
    1. Peterson KS, Winchester R. Systemic lupus erythematosus. In: William JK, Larry WM, editors. Pathogenesis. Philadelphia, Pa, USA: Lippincott Williams & Wilikins; 2005. pp. 1523–1559.
    1. Kirou KA, Crow MK. New pieces to the SLE cytokine puzzle. Clinical Immunology. 1999;91(1):1–5.
    1. Ginus LC, Cosim AB, Morris PJ. Transplantation. Oxford, UK: Blackwell Science; 1999.
    1. Sakuma S, Kato Y, Nishigaki F, et al. FK506 potently inhibits T cell activation induced TNF-α and IL-1β production in vitro by human peripheral blood mononuclear cells. British Journal of Pharmacology. 2000;130(7):1655–1663.
    1. Sakuma S, Higashi Y, Sato N, et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids) International Immunopharmacology. 2001;1(6):1219–1226.
    1. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. Journal of Rheumatology. 2003;30(10):2193–2200.
    1. Sakuma S, Kato Y, Nishigaki F, et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. International Immunopharmacology. 2001;1(4):749–757.
    1. Furukawa Y, Yoshikawa H, Iwasa K, Yamada M. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. Journal of Neuroimmunology. 2008;195(1-2):108–115.
    1. Sugiyama M, Funauchi M, Yamagata T, et al. Predominant inhibition of Th1 cytokines in New Zealand black/white F1 mice treated with FK506. Scandinavian Journal of Rheumatology. 2004;33(2):108–114.
    1. Jiang H, Wynn C, Pan F, Ebbs A, Erickson LM, Kobayashi M. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation. 2002;73(11):1808–1817.
    1. Llorente L, Richaud-Patin Y. The role of interleukin-10 in systemic lupus erythematosus. Journal of Autoimmunity. 2003;20(4):287–289.
    1. Heidt S, Roelen DL, Eijsink C, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. The Journal of Translational Immunology. 2009;159(2):199–207.
    1. Blanco P, Pitard V, Viallard J-F, Taupin J-L, Pellegrin J-L, Moreau J-F. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis and Rheumatism. 2005;52(1):201–211.
    1. Couzi L, Merville P, Deminiere C, et al. Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis. Arthritis and Rheumatism. 2007;56(7):2362–2370.
    1. Glassock RJ. Multitarget therapy of lupus nephritis: base hit or home run? Journal of the American Society of Nephrology. 2008;19(10):1842–1844.
    1. Millan O, Brunet M, Campistol JM, et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clinical Chemistry. 2003;49(11):1891–1899.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅